Pulmonary embolism future or investigational therapies

Pulmonary Embolism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pulmonary Embolism from other Diseases
Epidemiology and Demographics
Risk Factors
Triggers
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
Assessment of Clinical Probability and Risk Scores
Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores
History and Symptoms
Physical Examination
Laboratory Findings
Arterial Blood Gas Analysis
D-dimer
Biomarkers
Electrocardiogram
Chest X Ray
Ventilation/Perfusion Scan
Echocardiography
Compression Ultrasonography
CT
MRI
Treatment
Treatment approach
Medical Therapy
IVC Filter
Pulmonary Embolectomy
Pulmonary Thromboendarterectomy
Discharge Care and Long Term Treatment
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Follow-Up
Support group
Special Scenario
Pregnancy
Cancer
Trials
Landmark Trials
Case Studies
Case #1
Pulmonary embolism future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pulmonary embolism future or investigational therapies
CDC on Pulmonary embolism future or investigational therapies
Pulmonary embolism future or investigational therapies in the news
Blogs on Pulmonary embolism future or investigational therapies
Directions to Hospitals Treating Pulmonary embolism future or investigational therapies
Risk calculators and risk factors for Pulmonary embolism future or investigational therapies

Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

There are several ongoing studies on future therapies for the treatment and prevention of venous thromboembolism (VTE). The APEX study is a multicenter, randomized, active-controlled efficacy and safety study comparing extended duration betrixaban with standard of care enoxaparin for the prevention of VTE in acute medically ill patients. MARINER is a randomized, double-blind, placebo-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for VTE that aims to evaluate rivaroxaban in the prevention of symptomatic VTE events and VTE-related deaths for a period of 45 days post-hospital discharge.